Coltene wächst dank Akquisitionen

While sales are significantly higher, the integration of the acquired companies and new regulatory requirements have a negative impact on earnings.
(AWP) The dental supplies manufacturer Coltene (CLTN 91.3 -1.4%) grew strongly in 2019 mainly thanks to acquisitions. However, the integration of the acquired companies and new regulatory requirements had a negative impact on the result.

According to provisional figures, sales rose by 34% from Friday to CHF 273.8 million. This was due to the purchase of the companies SciCan and Micro-Mega, explained Coltene. Overall, however, the past year was a difficult year for the dental industry.

The integration of the new companies was going well, but the costs were higher than expected. One-off costs also resulted from the introduction of a new regulation on medical devices.

With an operating result (EBIT) of CHF 31.8 million, Coltene kept the margin of 11.6%. And the shareholders are to receive an unchanged dividend of CHF 3 per share.

The group believes that it is well equipped for the future. Management maintains its medium-term goal of an EBIT margin of 15% and sales growth slightly above the market.